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Introduction
Initial attempts delivered the insulin hormone intramuscularly, 
intravenously, and eventually subcutaneously. Other routes of 
administration of the drug were explored. These included oral, 
rectal, sublingual, buccal, transdermal, vaginal, intramuscular, 
intrapulmonary, and intranasal delivery systems. The purpose of 
these latter studies was to determine a noninjectable method to 
deliver insulin to patients with type 1 and 2 diabetes that would 
effectively lower blood sugar, control hemoglobin A1c (in much 
later studies), and allow patients a simpler, less invasive, and 
more direct control oftheir underlying disease process. 
In January 2006 the United States Food and Drug Administration 
approved Exubera (Pfizer Pharmaceuticals, New York, NY) as 
the first pulmonary inhaled insulin. In actuality attempts to explore 
various methods to deliver insulin using intrapulmonary delivery 
had occurred since1925. 
Summary
Intrapulmonary Insulin
The lung has been considered a route for systemic delivery of 
many therapeutic proteins and peptides. This system includes 
two major anatomical parts. The first includes the upper airways, 
oral cavity, trachea, bronchi, and all upper airways distal to the 
bronchioles. The second includes the lower airways, conducting 
airways including respiratory bronchioles, alveolar ducts, and 
alveolar sacs. The lung offers a large surface area for drug 
absorption (w75 m2). The very thin alveolar epithelium (w0.1–0.5 
mm thick) permits rapid drug absorption. The alveoli can be 
targeted for effective drug absorption by drug delivery by aerosol 
with a mass medium aerodynamic particle diameter <5 mm.
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Pulmonary barrier and pulmonary absorption
Although alveolar and capillary epithelia may be highly 
permeable to water permeation of many hydrophilic substances, 
absorption of moieties of large molecular size and ionic species is 
limited. Molecular weight cutoff of tight junctions for absorption by 
alveolar type I cells is 0.6 mm, although endothelial junctions 
allow passage of larger molecules (4–6 mm)
After reaching the alveoli many proteins are degraded by 
proteases or are removed by alveolar macrophages that secrete 
short-lived peroxidases, inflammatory and immunomodulatory 
mediators [including granulocyte colony stimulating factor 
(GCSF), interleukins, leukotrienes, and proteases], and other 
host-defense molecules. These molecules degrade inhaled 
peptides and proteins.
Intranasal Insulin
Delivery of intranasal insulin, as with intrapulmonary delivery, is 
dependent on many anatomic and physiologic factors that 
enhance and inhibit absorption. These include nasal mucus 
concentration, character of the nasal mucus ,speed of 
mucociliary clearance, character and thickness of the mucociliary 
membrane, nasal mucus enzymes, macrophages, and other cells 
that may act as barriers to intranasal absorption and—groups of 
moieties not present in pulmonary secretions—xenobiotics, 
bacteria, fungi, and other active microbial and antimicrobial 
agents present in the nose that are not present in the lower 
airways or in lung
What makes intranasal insulin administration more attractive than 
intrapulmonary administration is that absorption into the nose not 
only bypasses gastrointestinal inhibition of insulin absorption but 
also offers two important physiologic processes for insulin 
absorption: 1) absorption by the large available complex plexus 
of small blood vessels in the nose and 2) absorption that is not 
limited by the blood–brain barrier and can pass directly into the 
brain. The former method of absorption was measured indirectly 
by comparing levels of endogenous insulin in blood, nasal mucus, 
and saliva under varying conditions
Conclusion
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The Intranasal method of absorption, suggests that one aspect of 
these differences could relate to neural control of insulin 
metabolism through endogenous nasal absorption of insulin.
This hypothesis suggests that intranasal administration of insulin 
may offer a unique and useful method of insulin administration 
that may provide an important and novel method that could tap 
into important and heretofore unanticipated methods of control of 
insulin administration. This could not only control blood glucose 
directly but also control insulin effects on central nervous system 
(CNS) metabolism and secretion of substances by which insulin 
feedback mechanisms could be enhanced.
As with intrapulmonary delivery composition, the intranasal 
delivery system has been reported to play a significant role in 
insulin absorption. Intranasal absorption has been improved by 
using absorption enhancers such as aminoboronic acid 
derivatives, amastatin, and enzyme inhibitors . Surfactants, such 
as bile salts, have been reported to increase absorption by 
inhibiting the action of proteolytic enzymes present in nasal 
mucus . The variety of the composition of the intranasal delivery 
systems was reported to play a significant role in insulin 
absorption
The large surface area of the lung, its good vascularization, 
capacity for solute exchange and ultra thin membranes of 
alveolar epithelia are unique features that facilitate pulmonary 
insulin delivery. Large lung surface area (w75 m2) and thin 
alveolar epithelium (w0.1–0.5 mm) permit rapid drug absorption. 
First pass metabolism avoids gastrointestinal tract metabolism. 
Lung drug delivery depends upon a complex of factors including 
size, shape, density, charge and pH of delivery entity, velocity of 
entry, quality of aerosol deposition, character of alveoli, binding 
characteristics of aerosol on the alveolar surface, quality of 
alveolar capillary bed and its subsequent vascular tree. Intranasal 
insulin delivery faces a smaller surface area (w180 cm2) with 
quite different absorption characteristics in nasal epithelium and 
its associated vasculature. That makes the intransal insulin 
delivery more potent and efficacious than intrapulmonary insulin 
deliivery.
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Insulin absorption can be obtained by many routes of 
administration dependent on the characteristics of the insulin 
molecule, its absorption enhancement promoters, formulation of 
the delivery system, nature of the system into which insulin is to 
be delivered, ease and convenience of administration, and cost. 
These factors suggest that, although intrapulmonary insulin 
administration is not currently available, intranasal insulin 
administration may be a more effective non-invasive method of 
administration.
Fig 2: Comparison of Insulin delivery by different routes of 
administration.
Fig 3: Gamma camera scans showing the deposition of the
radioaerosol in the oropharynx (top) and lungs (bottom) of a 
patient with NIDDM
Advantages of Intranasal Insulin delivery
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